• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by VYNE Therapeutics Inc.

    5/15/25 5:28:40 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VYNE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    VYNE Therapeutics Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001

    (Title of Class of Securities)


    92941V308

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    92941V308


    1Names of Reporting Persons

    Citadel Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,040,070.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,040,070.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,040,070.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.8 %
    12Type of Reporting Person (See Instructions)

    IA, HC, OO

    Comment for Type of Reporting Person:  The percentages reported in this Schedule 13G are based upon 15,209,862 Shares outstanding as of February 27, 2025 (according to the issuer's Form 10-K as filed with the Securities and Exchange Commission on March 6, 2025).


    SCHEDULE 13G

    CUSIP No.
    92941V308


    1Names of Reporting Persons

    Citadel Advisors Holdings LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,040,070.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,040,070.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,040,070.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.8 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP No.
    92941V308


    1Names of Reporting Persons

    Citadel GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,040,070.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,040,070.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,040,070.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.8 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    92941V308


    1Names of Reporting Persons

    Citadel Securities LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    58,260.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    58,260.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    58,260.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    BD, OO


    SCHEDULE 13G

    CUSIP No.
    92941V308


    1Names of Reporting Persons

    Citadel Securities Group LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    60,259.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    60,259.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    60,259.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP No.
    92941V308


    1Names of Reporting Persons

    Citadel Securities GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    60,259.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    60,259.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    60,259.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    92941V308


    1Names of Reporting Persons

    Kenneth Griffin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,100,329.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,100,329.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,100,329.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    VYNE Therapeutics Inc.
    (b)Address of issuer's principal executive offices:

    685 Route 202/206 N, Suite 301, Bridgewater, New Jersey 08807
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being jointly filed by Citadel Advisors LLC ("Citadel Advisors"), Citadel Advisors Holdings LP ("CAH"), Citadel GP LLC ("CGP"), Citadel Securities LLC ("Citadel Securities"), Citadel Securities Group LP ("CALC4"), Citadel Securities GP LLC ("CSGP") and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the "Reporting Persons") with respect to the Shares of the above-named issuer owned by Citadel CEMF Investments Ltd., a Cayman Islands limited company ("CCIL"), CRBU Holdings LLC, a Delaware limited liability company ("CRBH"), and Citadel Securities. Such owned Shares may include other instruments exercisable for or convertible into Shares. Citadel Advisors is the portfolio manager for CCIL. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of CRBH and Citadel Securities. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP. The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
    (b)Address or principal business office or, if none, residence:

    The address of each of CSGP, Citadel Securities and CALC4 is 830 Brickell Plaza, Miami, Florida 33131. The address of the other Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131.
    (c)Citizenship:

    Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.
    (d)Title of class of securities:

    Common Stock, par value $0.0001
    (e)CUSIP No.:

    92941V308
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 1,040,070 Shares. 2. Citadel Securities LLC may be deemed to beneficially own 58,260 Shares. 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 60,259 Shares. 4. Mr. Griffin may be deemed to beneficially own 1,100,329 Shares.
    (b)Percent of class:

    1. The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 6.8% of the Shares outstanding. 2. The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.4% of the Shares outstanding. 3. The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.4% of the Shares outstanding. 4. The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 7.2% of the Shares outstanding.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0 2. Citadel Securities LLC: 0 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0 4. Mr. Griffin: 0

     (ii) Shared power to vote or to direct the vote:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 1,040,070 2. Citadel Securities LLC: 58,260 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 60,259 4. Mr. Griffin: 1,100,329

     (iii) Sole power to dispose or to direct the disposition of:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 0 2. Citadel Securities LLC: 0 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 0 4. Mr. Griffin: 0

     (iv) Shared power to dispose or to direct the disposition of:

    1. Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC: 1,040,070 2. Citadel Securities LLC: 58,260 3. Each of Citadel Securities Group LP and Citadel Securities GP LLC: 60,259 4. Mr. Griffin: 1,100,329

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Citadel Advisors LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:05/15/2025
     
    Citadel Advisors Holdings LP
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:05/15/2025
     
    Citadel GP LLC
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, Authorized Signatory
    Date:05/15/2025
     
    Citadel Securities LLC
     
    Signature:/s/ Guy Miller
    Name/Title:Guy Miller, Authorized Signatory
    Date:05/15/2025
     
    Citadel Securities Group LP
     
    Signature:/s/ Guy Miller
    Name/Title:Guy Miller, Authorized Signatory
    Date:05/15/2025
     
    Citadel Securities GP LLC
     
    Signature:/s/ Guy Miller
    Name/Title:Guy Miller, Authorized Signatory
    Date:05/15/2025
     
    Kenneth Griffin
     
    Signature:/s/ Seth Levy
    Name/Title:Seth Levy, attorney-in-fact*
    Date:05/15/2025

    Comments accompanying signature:  * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.
    Get the next $VYNE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VYNE

    DatePrice TargetRatingAnalyst
    7/31/2025Buy → Neutral
    BTIG Research
    11/18/2024$8.00Buy
    BTIG Research
    12/6/2021$7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $VYNE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

    BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today reported financial results as of and for the quarter ended June 30, 2025. The Company is actively evaluating opportunities to enhance the value of its pipeline programs. VYNE's oral BD2-selective BET inhibitor, VYN202, has recently demonstrated a promising efficacy signal in a Phase 1b clinical trial in moderate to severe plaque psoriasis, as well as disease-modifying potential across multiple tran

    8/14/25 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

    Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Baseline in F-VASI and T-VASI at 3% Concentration Company Will Terminate Extension Phase of Trial and Seek External Partner for Continued Development of Repibresib BRIDGEWATER, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced topline results from its P

    7/30/25 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

    BRIDGEWATER, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today provided a program update for VYN202 following the clinical hold issued by the U.S. Food and Drug Administration (FDA) in April for the Company's Phase 1b clinical trial in the treatment of moderate-to-severe plaque psoriasis. VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immune-mediated diseases.   

    7/2/25 7:45:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    SEC Filings

    View All

    VYNE Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - VYNE Therapeutics Inc. (0001566044) (Filer)

    9/12/25 4:03:33 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by VYNE Therapeutics Inc.

    SCHEDULE 13G/A - VYNE Therapeutics Inc. (0001566044) (Subject)

    8/14/25 4:49:29 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - VYNE Therapeutics Inc. (0001566044) (Filer)

    8/14/25 8:05:47 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 2,453 shares, decreasing direct ownership by 2% to 117,687 units (SEC Form 4)

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    10/2/25 5:05:09 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 12,676 shares, decreasing direct ownership by 3% to 428,892 units (SEC Form 4)

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    10/2/25 5:05:05 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 3,420 shares, decreasing direct ownership by 3% to 111,653 units (SEC Form 4)

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    10/2/25 5:05:10 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    VYNE Therapeutics downgraded by BTIG Research

    BTIG Research downgraded VYNE Therapeutics from Buy to Neutral

    7/31/25 7:17:36 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on VYNE Therapeutics with a new price target

    BTIG Research initiated coverage of VYNE Therapeutics with a rating of Buy and set a new price target of $8.00

    11/18/24 7:58:59 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. resumed coverage on VYNE Therapeutics with a new price target

    HC Wainwright & Co. resumed coverage of VYNE Therapeutics with a rating of Buy and set a new price target of $7.00

    12/6/21 6:30:12 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lepore Patrick G bought $43,800 worth of shares (15,000 units at $2.92), increasing direct ownership by 41% to 51,472 units (SEC Form 4)

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    1/16/25 6:06:19 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lepore Patrick G bought $50,778 worth of shares (13,000 units at $3.91), increasing direct ownership by 55% to 36,472 units (SEC Form 4)

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    11/17/23 5:03:12 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Leadership Updates

    Live Leadership Updates

    View All

    VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

    BRIDGEWATER, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the appointment of Subhashis Banerjee, M.D., as Senior Vice President of Clinical Development, effective as of July 8, 2024. Dr. Banerjee is a trained immunologist and rheumatologist with over 25 years of drug development experience at large pharmaceutical companies, including with the development of therapies for psoriasis and arthritic conditions. "We are pleased to welcome Dr. Banerjee to the VYNE

    7/9/24 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

    BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the appointment of Christine Borowski, Ph.D., to its board of directors, effective as of January 1, 2024. "We are pleased to welcome Dr. Borowski to our Board of Directors during this important time in the Company's growth," said David Domzalski, President and CEO of VYNE. "With her expertise in immunology and extensive experience in the biopharmaceutical industry, Dr. Borowski will provide valuable p

    1/3/24 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by VYNE Therapeutics Inc.

    SC 13G/A - VYNE Therapeutics Inc. (0001566044) (Subject)

    11/14/24 3:34:53 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by VYNE Therapeutics Inc. (Amendment)

    SC 13G/A - VYNE Therapeutics Inc. (0001566044) (Subject)

    2/14/24 4:57:08 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by VYNE Therapeutics Inc. (Amendment)

    SC 13G/A - VYNE Therapeutics Inc. (0001566044) (Subject)

    2/2/24 9:42:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Financials

    Live finance-specific insights

    View All

    VYNE Therapeutics Announces Reverse Stock Split

    BRIDGEWATER, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that its Board of Directors has approved a reverse stock split of the Company's common stock at a ratio of 1-for-18. The reverse stock split was previously approved by stockholders at the Special Meeting of Stockholders on January 12, 2023. The reverse stock split will become effective after market close on Friday, February 10, 2023 and shares will begin trading on a split-adjusted basis when the market opens on Mo

    2/10/23 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

    Lead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies VYN201 Expected to Enter Clinic in 2022 Phase 2a Results for FMX114 in Mild-to-Moderate Atopic Dermatitis Expected Early Q1 2022 Process for Sale of Topical Minocycline Franchise Continues to Advance Conference call and Live Webcast Today at 8:30 am Eastern Time BRIDGEWATER, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced financial results for the third quarter ended September 30, 2021 and provided a business update. "The third quarter marks an important turning point for VYNE, as our company is now fully enga

    11/10/21 7:30:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021

    BRIDGEWATER, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced that it will report its financial results for the third quarter ended September 30, 2021, on Wednesday, November 10, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Details:Wednesday, November 10th @ 8:30am Eastern TimeToll Free:855-327-6837International:631-891-4304Conference ID:10017178Webcast:https://themediaframe.com/mediaframe/webcast.html?webcastid=44cKOFEX A replay of the call will be archived on the Company's website at

    10/28/21 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care